Pfizer: It’s Darkest Before The Dawn, Upgrading To ‘Strong Buy’

  • Pfizer’s Q4 FY2023 financials show a significant downturn in consolidated revenues, with a 93% decline in profit for the full year.
  • Sales of Comirnaty and Paxlovid, Pfizer’s COVID-related drugs, fell by 70% and 93% respectively in FY2023.
  • Despite the decline, Pfizer’s focus on innovation in oncology and cost-saving measures may help offset the effects of the drop in sales.
  • I calculate the growth potential at 100%+ in 4-5 years – and this doesn’t even include the dividend yield of 6%+ that a potential investor can secure at today’s prices.
  • I’ve therefore decided to upgrade PFE stock to “Strong Buy” today.
  • I am Danil Sereda, chief investment officer at a family office. I analyze information that ordinary retail investors do not have access to, and lead the investing group Beyond the Wall Investing.


On December 21, 2023, I wrote about Pfizer Inc. (NYSE:PFE) stock for the first time after a long hiatus since initiating coverage in November 2021. Last time, I wrote about PFE appearing oversold and undervalued due to likely